Klinikum Chemnitz

Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients (2025) Rautenberg C, Middeke JM, Röllig C, Stelljes M, Gaidzik V, Kriege O, Verbeek M, et al. Journal article The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML (2025) Stasik S, Eckardt JN, Röllig C, Baldus CD, Platzbecker U, Serve H, Müller-Tidow C, et al. Journal article Sub-optimale Behandlung von Patienten mit Primär Biliärer Cholangitis (PBC) im klinischen Alltag der deutschen PBC Kohorte Sub-optimal therapy of patients with primary biliary cholangitis (PBC) in the real-life stetting of the German PBC cohort (2024) Wiegand J, Franke A, Müller T, Stein K, Bantel H, Günther R, Denk G, et al. Journal article Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma – knowledge obtained from the CheckRad-CD8 trial (2024) Hecht M, Frey B, Gaipl U, Tianyu X, Eckstein M, Donaubauer AJ, Klautke G, et al. Journal article Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer (2024) Fasching P, Decker T, Hartkopf A, Nusch A, Heinrich BJ, Kurbacher C, Fuchs R, et al. Journal article Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL (2024) Stelljes M, Raffel S, Alakel N, Wäsch R, Kondakci M, Scholl S, Rank A, et al. Journal article Transoral laser microsurgery for supraglottic carcinomas: results of a prospective multicenter trial (SUPRATOL) (2024) Ambrosch P, Meuret S, Dietz A, Fazel A, Fietkau R, Tostmann R, Schroeder U, et al. Journal article Single or Double Induction With 7 1 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia (2024) Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, et al. Journal article De-intensification of postoperative radiotherapy in head and neck cancer irrespective of human papillomavirus status—results of a prospective multicenter phase II trial (DIREKHT Trial) (2024) Haderlein M, von der Grün J, Balermpas P, Rödel C, Hautmann MG, Steger F, Bohr C, et al. Journal article Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens. (2024) Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, Schliemann C, et al. Journal article